Khokhar Muhammad O, Kettle Jacob, Palla Amruth R
Division of Hematology and Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri Columbia, Columbia, MO, USA.
Division of Hematology and Oncology, Department of Pharmacy, Ellis Fischel Cancer Center, University of Missouri Columbia, Columbia, MO, USA.
Case Rep Oncol. 2016 Dec 8;9(3):833-839. doi: 10.1159/000452944. eCollection 2016 Sep-Dec.
Frequently described immune-mediated adverse effects of immune therapy include dermatological complications, hepatitis, colitis, pneumonitis, and endocrinopathies. As utilization of pembrolizumab and related agents continues to expand both in the available indications as well as duration of exposure, there remains a significant potential to uncover previously undescribed adverse events. From a dermatological standpoint, 39% of patients receiving pembrolizumab therapy experience some form of skin-related drug toxicity [Naidoo et al.: Ann Oncol 2015;26: 2375-2391]. We describe a case of pembrolizumab-induced disabling autoimmune ectodermal toxicity.
免疫疗法常见的免疫介导不良反应包括皮肤并发症、肝炎、结肠炎、肺炎和内分泌病。随着帕博利珠单抗及相关药物在现有适应证和暴露持续时间方面的应用不断扩大，仍有很大可能发现以前未描述的不良事件。从皮肤病学角度来看，接受帕博利珠单抗治疗的患者中有39%经历了某种形式的皮肤相关药物毒性[奈杜等人：《肿瘤学年鉴》2015年；26: 2375 - 2391]。我们报告一例帕博利珠单抗诱发的致残性自身免疫性外胚层毒性病例。
